B+
Bull case
25%
Probability
Target price
$9.25
+30.6% vs current
INNV
InnovAgeDNasdaq / Health Care Equipment & Services
Last Price
At close
2026-06-03
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
50%
Probability
Target price
$7.25
+2.4% vs current
B-
Bear case
25%
Probability
Target price
$5.75
-18.8% vs current
AI sentiment snapshot
Latest data as of 2026-05-08
Recent news sentiment (30D)
-26.5
Negative
Company
-
Unavailable
Macro
-26.5
Negative
Pulse
-
Unavailable
Sentiment proxy
+51.1
Score
AI commentary
This is still a monitoring-style post-earnings memo rather than a clean bullish upgrade. Company-source evidence is strong and the initial May 5, 2026 earnings reaction was positive, but by May 8, 2026 the stock was about $8.00 versus the $8.08 May 7 anchor, implying much of the first pop had faded. Analyst revision visibility remains thin, so the better tone from the earnings package should raise attention more than conviction.
RankAlpha Sentiment Codex - 2026-05-08
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-06-30catalystCash build and operating cash flow reduce immediate financing pressureMedium impact
InnovAge ended March 31, 2026 with $95.5 million of cash, $43.1 million of short-term investments, $69.4 million of debt, and $43.4 million of operating cash flow for the first nine months of fiscal 2026, which lowers near-term balance-sheet risk even if it is not a standalone rerating driver [#10-Q-2026-05-08] [#8-K-2026-05-05].
2026-09-09eventQ4/FY2026 report must prove the Q3 guide raise can survive a tougher FY2027 rate backdropHigh impact
The May 5 earnings package raised FY2026 revenue guidance to $950-$975 million and Adjusted EBITDA to $85-$90 million, but management also said early FY2027 Medicaid indications look softer and Medicare rate growth may be only about 1.5%-2.0%, making the next quarterly update the key proof point for whether current margin gains are durable [#8-K-2026-05-05].
2026-12-31catalystCenter-level margin gains can continue if census growth and care-cost control holdHigh impact
Q3 revenue rose 15.5% year over year to $251.9 million, center-level contribution margin improved to 24.2% from 18.7%, and management attributed the improvement to higher capitation rates, member-month growth, lower nursing-facility utilization, in-house pharmacy benefits, and better medical-cost discipline while newer Florida centers continue to mature [#8-K-2026-05-05] [#10-K-2025-09-09].
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-08 • Updated nightlySource: Internal modelMethodology